Startup Raises $250M to Help Dogs Live Longer Lives

Loyal, a canine health startup, just raised $250 million to help your dog stick around longer—and the science behind it could one day help humans too.

The company announced $100 million in Series C funding on February 11 as it races toward FDA approval for LOY-002, a beef-flavored daily pill designed to keep senior dogs healthier for more years. If approved later this year, it would become the first FDA-approved lifespan extension drug for any species.

The medication mimics the benefits of calorie restriction on age-related metabolism without making dogs eat less. That matters more than you might think.

"People do not want their dogs to not have food motivation, because that's how you train dogs," says founder and CEO Celine Halioua. "How we domesticated dogs was sharing meals with them; losing that can actually really impact the dog-human bond."

Halioua started Loyal in late 2019 after working at The Longevity Fund, an investment fund focused on extending human lifespans. She realized dogs made perfect test subjects because they age much faster than humans, share similar biology, and desperately need the help—most dogs only live 10 to 15 years.

The company is developing three different longevity medications for dogs. Halioua hopes to submit the final paperwork for LOY-002's expanded conditional approval this year, which would trigger a six-month FDA review process.

The Ripple Effect

The implications stretch far beyond our four-legged friends. Dogs' shorter lifespans mean researchers can test age-extension treatments in just a few years instead of decades. Success in canine trials could fast-track similar medications for humans.

The investment world has noticed. Laura Deming, who founded The Longevity Fund and backed Loyal early, says the shift has been dramatic. "When I started pitching The Longevity Fund in 2013, it was a niche concept and people laughed me out of their offices," she says. "Now it's a legitimate category of investment."

The $250 million raised by Loyal signals growing confidence that longevity science isn't just theoretical anymore. Real treatments are coming, starting with the pets we love.

For now, Loyal is solving a problem every dog owner understands: we simply don't get enough time with our best friends.